Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%
Ashley Jackson, Nina Chang, Deborah Akurang, Paul Wheatley-Price, Sara Moore · 2023
Read Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90% by Ashley Jackson, Nina Chang, Deborah Akurang, Paul Wheatley-Price, Sara Moore (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10755357.txt.
Description
A peer-reviewed research article from Europe PMC (2023). BackgroundImmunotherapy has vastly changed the treatment landscape for patients with advanced NSCLC. With high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥50%), options include programmed cell death protein 1 or PD-L1 inhibitor with or without chemotherapy. A cut-point of greater than or equal to 50% defines PD-L1–high, but a more precise PD-L1 tumor proportion score may be an important predictor of outcomes.MethodsWe reviewed all patients with PD-L1–high NSCLC who received pembrolizumab from June 2019 to June 2021.
Catalog record
| CREATOR | Ashley Jackson, Nina Chang, Deborah Akurang, Paul Wheatley-Price, Sara Moore |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |